6Indexed trials
drug · Product Intelligence
Pimavanserin
Pipeline Intelligence
Pimavanserin: 6 indexed trials, 2 sponsors; 17 linked Orange Book patents and 9 FDA-linked events where matched.
2Sponsors
17Orange Book patent links
9FDA-linked events
Development evidence
NCT03018340ACADIA Pharmaceuticals Inc. · depressionPHASE2
NCT03482882ACADIA Pharmaceuticals Inc. · parkinsonsPHASE2
NCT04164758ACADIA Pharmaceuticals Inc. · parkinsonsPHASE2
NCT04292223ACADIA Pharmaceuticals Inc. · parkinsonsPHASE4
NCT04373317VA Office of Research and Development · parkinsonsPHASE4
NCT05523895ACADIA Pharmaceuticals Inc. · autismPHASE2, PHASE3
FDA / patent evidence
10449185*PEDNUPLAZID · app 2107932039-02-27
10646480*PEDNUPLAZID · app 2107932039-02-27
11452721*PEDNUPLAZID · app 2107932039-02-27
10849891*PEDNUPLAZID · app 2107932039-02-27
10449185NUPLAZID · app 2107932038-08-27
10646480NUPLAZID · app 2107932038-08-27
10849891NUPLAZID · app 2107932038-08-27
11452721NUPLAZID · app 2107932038-08-27
10517860*PEDNUPLAZID · app 2073182037-09-23
10953000*PEDNUPLAZID · app 2073182037-09-23
10953000NUPLAZID · app 2073182037-03-23
10517860NUPLAZID · app 2073182037-03-23
Regulatory context
FDA_EXCLUSIVITYNUPLAZID · PED2029-10-27
FDA_EXCLUSIVITYNUPLAZID · PED2029-10-27
FDA_EXCLUSIVITYNUPLAZID · M-142029-04-27
FDA_EXCLUSIVITYNUPLAZID · M-142029-04-27
FDA_APPROVALPIMAVANSERIN · 2024-01-16
FDA_APPROVALPIMAVANSERIN · 2024-01-16
FDA_APPROVALPIMAVANSERIN · 2024-01-16
FDA_APPROVALNUPLAZID · 2018-06-28
FDA_APPROVALNUPLAZID · 2018-06-28
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.